Detalles de la búsqueda
1.
Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
Gynecol Oncol
; 184: 24-30, 2024 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38277918
2.
Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects.
Support Care Cancer
; 32(3): 202, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38427111
3.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 24(3): 286-296, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37052965
4.
Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group.
Curr Oncol Rep
; 24(7): 843-860, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35320498
5.
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
Future Oncol
; 18(7): 771-779, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35068173
6.
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Lancet Oncol
; 22(2): 267-276, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33539744
7.
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study.
Support Care Cancer
; 29(7): 3971-3980, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33392769
8.
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.
Int J Gynecol Cancer
; 31(7): 1031-1036, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33990353
9.
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Int J Gynecol Cancer
; 31(6): 875-882, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33931498
10.
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Int J Gynecol Cancer
; 31(10): 1348-1355, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34462317
11.
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
Breast Cancer Res
; 22(1): 115, 2020 10 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33109233
12.
EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer.
Breast Cancer Res
; 22(1): 83, 2020 08 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32758299
13.
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
Br J Cancer
; 123(1): 26-32, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32346071
14.
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity.
Future Oncol
; 16(5): 129-145, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31849236
15.
Oral anticancer therapy project: Clinical utility of a specific home care nursing programme on behalf of Italian Association of Medical Oncology (AIOM).
J Clin Nurs
; 29(1-2): 119-129, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31532035
16.
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.
Breast Cancer Res
; 21(1): 71, 2019 05 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-31142370
17.
Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.
Oncologist
; 24(6): e232-e240, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30413667
18.
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.
Oncologist
; 24(3): 385-393, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30606884
19.
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.
Pharmacogenomics J
; 19(6): 556-563, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30723313
20.
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
BMC Cancer
; 19(1): 283, 2019 Mar 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-30922323